NCT07191483 - A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2026

Conditions

Cognitive Impairment Associated With Schizophrenia (CIAS)

Interventions

DRUG

KYN-5356 low dose

oral tablet

OTHER

Placebo

Oral tablet

DRUG

KYN-5356 Medium Dose

oral tablet

DRUG

KYN-5356 High Dose

oral tablet

Trial Locations (13)

20877

RECRUITING

Cenexel CBH, Gaithersburg

30030

RECRUITING

Cenexel iResearch Atlanta, Decatur

30331

RECRUITING

Cenexel ACMR, Atlanta

33016

RECRUITING

Segal Trials, Miami Lakes

33024

RECRUITING

Cenexel RCA, Hollywood

44720

RECRUITING

Neuro-Behavioral Clinical Research, North Canton

60640

RECRUITING

Uptown Research Institute, Chicago

63125

RECRUITING

Arch Clinical Trials, St Louis

72211

RECRUITING

Woodland International Research Group, Little Rock

78754

RECRUITING

Community Clinical Research, Austin

90720

RECRUITING

Cenexel CNS, Los Alamitos

92064

RECRUITING

Synergy Research Center, Lemon Grove

08053

RECRUITING

Cenexel HRI, Marlton